Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial
Authors:
- Karim AliKAKarim Ali
- Tanweer AzherTATanweer Azher
- Mahin BaqiMBMahin Baqi
- Alexandra BinnieABAlexandra Binnie
- Sergio BorgiaSBSergio Borgia
- François M. CarrierFCFrançois M. Carrier
- Yiorgos Alexandroa CavayasYCYiorgos Alexandroa Cavayas
- Nicolas ChagnonNCNicolas Chagnon
- Matthew P. ChengMCMatthew P. Cheng
- John ConlyJCJohn Conly
- Cecilia CostiniukCCCecilia Costiniuk
- Peter DaleyPDPeter Daley
Top Cited Papers
Open Access
- 19 January 2022
- journal article
- research article
- Published by CMA Impact Inc. in Canadian Medical Association Journal
- Vol. 194 (7) , E242-E251
Abstract
Background: The role of remdesivir in the treatment of patients in hospital with COVID-19 remains ill defined in a global context. The World Health Organization Solidarity randomized controlled trial (RCT) evaluated remdesivir in patients across many countries, with Canada enrolling patients using an expanded data collection format in the Canadian Treatments for COVID-19 (CATCO) trial. We report on the Canadian findings, with additional demographics, characteristics and clinical outcomes, to explore the potential for differential effects across different health care systems. Methods: We performed an open-label, pragmatic RCT in Canadian hospitals, in conjunction with the Solidarity trial. We randomized patients to 10 days of remdesivir (200 mg intravenously [IV] on day 0, followed by 100 mg IV daily), plus standard care, or standard care alone. The primary outcome was in-hospital mortality. Secondary outcomes included changes in clinical severity, oxygen- and ventilator-free days (at 28 d), incidence of new oxygen or mechanical ventilation use, duration of hospital stay, and adverse event rates. We performed a priori subgroup analyses according to duration of symptoms before enrolment, age, sex and severity of symptoms on presentation. Results: Across 52 Canadian hospitals, we randomized 1282 patients between Aug. 14, 2020, and Apr. 1, 2021, to remdesivir (n = 634) or standard of care (n = 648). Of these, 15 withdrew consent or were still in hospital, for a total sample of 1267 patients. Among patients assigned to receive remdesivir, in-hospital mortality was 18.7%, compared with 22.6% in the standard-of-care arm (relative risk [RR] 0.83 (95% confidence interval [CI] 0.67 to 1.03), and 60-day mortality was 24.8% and 28.2%, respectively (95% CI 0.72 to 1.07). For patients not mechanically ventilated at baseline, the need for mechanical ventilation was 8.0% in those assigned remdesivir, and 15.0% in those receiving standard of care (RR 0.53, 95% CI 0.38 to 0.75). Mean oxygen-free and ventilator-free days at day 28 were 15.9 (± standard deviation [SD] 10.5) and 21.4 (± SD 11.3) in those receiving remdesivir and 14.2 (± SD 11) and 19.5 (± SD 12.3) in those receiving standard of care (p = 0.006 and 0.007, respectively). There was no difference in safety events of new dialysis, change in creatinine, or new hepatic dysfunction between the 2 groups. Interpretation: Remdesivir, when compared with standard of care, has a modest but significant effect on outcomes important to patients and health systems, such as the need for mechanical ventilation. Trial registration: ClinicalTrials.gov, no.NCT04330690.Keywords
This publication has 24 references indexed in Scilit:
- Remdesivir for 5 or 10 Days in Patients with Severe Covid-19New England Journal of Medicine, 2020
- Remdesivir for the Treatment of Covid-19 — Final ReportNew England Journal of Medicine, 2020
- A minimal common outcome measure set for COVID-19 clinical researchThe Lancet Infectious Diseases, 2020
- Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trialThe Lancet, 2020
- Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (April 2020)Clinical Infectious Diseases, 2020
- Reappraisal of Ventilator-Free Days in Critical Care ResearchAmerican Journal of Respiratory and Critical Care Medicine, 2019
- Interpreting Geographic Variations in Results of Randomized, Controlled TrialsNew England Journal of Medicine, 2016
- Pragmatic TrialsNew England Journal of Medicine, 2016
- Critical care and the global burden of critical illness in adultsThe Lancet, 2010
- Variation in critical care services across North America and Western Europe*Critical Care Medicine, 2008